KODIAK SCIENCES INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 3.83 USD | +6.09% |
|
-2.79% | +25.99% |
Presenter SpeechAndrea Tan (Analysts)Thanks, everyone, for joining us for the last session of ...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Kodiak Sciences Inc. is a biopharmaceutical company. The Company has developed a new technology platform, the Antibody Biopolymer Conjugate (ABC) Platform, for retinal medicines. Its ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies. Its lead investigational medicine, tarcocimab, is a novel anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer conjugate under development for the treatment of high prevalence retinal vascular diseases, including diabetic retinopathy, the cause of blindness in working-age patients in the developed world, and wet age-related macular degeneration, the cause of blindness in elderly patients. Its second investigational medicine, KSI-501, is a bispecific antibody biopolymer conjugate targeting the pro-inflammatory cytokine interleukin-6 (IL-6) and VEGF. It is also developing a third investigational medicine, KSI-101, an unconjugated bispecific protein targeting IL-6 and VEGF.
Calendar
2024-06-04
- Annual General Meeting
Related indices
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
3.83
USD
Average target price
4.25
USD
Spread / Average Target
+10.97%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +25.99% | 201M | |
| +5.66% | 111B | |
| +11.23% | 105B | |
| -12.15% | 22.34B | |
| -2.68% | 21.93B | |
| -5.61% | 18.59B | |
| -36.52% | 18.12B | |
| -10.09% | 16.96B | |
| +3.33% | 13.7B | |
| +36.58% | 12.45B |
- Stock Market
- Equities
- KOD Stock
- News Kodiak Sciences Inc.
- Transcript : Kodiak Sciences Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 04